# A Phase II Safety and Tolerability Study of TCB008 in Patients With COVID-19

> **NCT04834128** · PHASE2 · WITHDRAWN · sponsor: **TC Biopharm**

## Conditions studied

- COVID - 19

## Interventions

- **DRUG:** TCB008

## Key facts

- **NCT ID:** NCT04834128
- **Lead sponsor:** TC Biopharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-12-13
- **Primary completion:** 2022-04-13
- **Final completion:** 2022-04-13
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was stopped because of the current status of the COVID-19 epidemic in the United Kingdom, and also because the trial involved parenterally administered IMP and a period of inpatient care and extensive outpatient visits and investigations.
- **Last updated:** 2023-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04834128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04834128, "A Phase II Safety and Tolerability Study of TCB008 in Patients With COVID-19". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04834128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*